2020 MDMA Medical Technology Executive Forum Agenda

 


                    

*Speakers will be added as confirmed

Click Here for a PDF of the Agenda

 Friday, September 25, 2020 - 11:00am-3:00pm ET

 

11:00am – 11:05am

Welcoming Remarks

  • Mark Leahey, President & CEO, MDMA

11:05am – 11:20am

Keynote CMS Update

Administrator Verma & MDMA's President & CEO, Mark Leahey will present a virtual fireside chat to discuss key CMS priorities.

  • Seema Verma, Administrator of the Centers for Medicare & Medicaid Services

11:20am – 12:00pm

CMS Update

CMS has issued several new proposed rules and regulations that will expedite patient access to innovative medical technologies, including the recent “Medicare Coverage of InnovativeTechnology.”  Hear from one of the agency’s top policymakers what this will mean for your ability to grow, and to continue improving patient outcomes.

  • Tamara Syrek Jensen, Director, Coverage and Analysis Group, Centers for Medicare & Medicaid Services

12:00pm – 12:45pm
2020 Election Preview:  Predictions and Their Impact
Control of Congress and the White House will be on the ballot in 2020, and some of the nation’s leading strategists will share their insights on the state of the races, as well as what the various outcomes will mean for business and innovation. This bipartisan, interactive panel will answer attendees’ questions and focus on the elections’ impact on health care, trade issues, infrastructure and much more.

  • Josh Holmes, President, Founding Partner, Cavalry, LLC
  • Andrew Rosenberg, Partner, Thorn Run Partners
12:45pm – 1:00pm

Break

 

1:00pm – 2:00pm

CDRH Update

Director Shuren will focus on the latest policies and strategies the FDA is developing to confront the COVID-19 pandemic, and his interactive session will allow you to ask your questions to him directly.  As MDMA and other stakeholders are set to begin the MDUFA reauthorization negotiations in the fall, this will be a unique opportunity to learn what the agency will be focusing on, and how we can all work collaboratively to continue developing innovative medical technologies.

  •  Jeffery Shuren, MD, Director, CDRH, FDA

2:00pm – 2:20pm

Perspectives from the C-Suite

Learn from one of our industry’s top CEOs what it took to thrive while confronting the challenges posed by COVID-19, and how to plan for the future as the nation and the world address the “new normal.”

  • Leslie Trigg, Chief Executive Officer, Outset Medical

2:20pm – 2:40pm

How Big Data Can Change Your Investment Strategy
Learn the latest strategies to use health care data to make strategic investment decisions. Medical device manufacturers and financial services firms alike want to make the wisest use of their investment dollars. Join this fireside chat to learn how data can be used to inform investment strategies, market profiling and more.

  • Russell Robbins, MD, AVP Clinical Informatics & Medical Director, Blue Health Intelligence

2:40pm – 3:00pm

Patent Strategy and Associated Costs During Medical Device Development

This panel will discuss patent protection and product clearance strategies to consider during medical device development.  Average costs for these strategies will also be provided to allow R&D budgeting.  Finally, strategies to delay immediate patent costs while maintaining patent rights in view of potential COVID-19 related budget restrictions will be reviewed.

  • Hussein Akhavannik, Partner, BakerHostetler

3:00pm

Closing Remarks

 

         

Sessions and speakers are subject to change without notice. MDMA reserves the right to cancel or reschedule any program, whereupon full registration fees will be refunded or applied to the rescheduled program in accordance with the registrant's preference. In the event of canceled programs, MDMA assumes no responsibility for transportation, hotel, or other expenses incurred by registrants.